Home / BUSINESS / Competition Council starts probing into the market of non-prescription medicines and food supplements
Competition Council starts probing into the market of non-prescription medicines and food supplements

Competition Council starts probing into the market of non-prescription medicines and food supplements

The Competition Council has launched an investigation into the production and sale of non-prescription medicines and of food supplements. The inspectors will probe into the structural conditions of the markets, the existing contracts in this sector, while also conducting a detailed analysis of the enforceable legislative framework.

If malfunctions which affect the competition environment are identified, the Council will propose amendments or revision of the existing laws in order to protect the economic efficiency of the sector and to protect the consumers’ interests, says a press release by the Competition Council. The authority might also start investigations on potential violations of law.

The pharmaceutical sector is very important to us, and the activity in the past years proves it: we have made several recommendations on the draft laws, and we also got involved in investigations on anti-competition conducts in the field,” says the Competition Council president, Bogdan Chiritoiu.

The council has conducted several analyses on the pharma industry, with some recommendations being taken over and enforced by the Health Ministry in this sector, such as the proposal that there is a similar price for the generic medicine and the innovative one.

Also, upon the proposal of the Competition Council, the geographic criteria that prevented the opening of a new pharmacy has been removed, which improved the patients’ access to the pharmaceutical services.

In June end, The Competition Council has launched an investigation into a possible understanding between some companies authorised for manufacturing and marketing human normal immunoglobulin.

Under scrutiny are Biotest Pharma GmbH Germany, Octapharma Pharmazeutika Produktionsges Mbh Austria, Octapharma S.A.S. France, Octapharma AB Sweden, Octapharma (IP) Limited United Kingdom, CSL Behring Gmbh Germany, Kedrion Spa Italy, Baxter SA Belgium, Baxalta Belgium Manufacturing SA Belgium, Baxter AG Austria.

At the same time, two investigations into a possible abuse of the dominant position of Roche Romania SRL on the Romanian oncologic market are under way.

About Romania Journal